Home Biosimilar Antibodies Metabolism Carbonic Anhydrase Girentuximab (Anti-CA9 / Carbonic anhydrase 9)
For research use only. Not for use in humans.

Girentuximab (Anti-CA9 / Carbonic anhydrase 9)

Synonyms: G250; cG250

Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to Carbonic Anhydrase IX (CAIX) / Carbonic Anhydrase 9 (CA9), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD.

Girentuximab (Anti-CA9 / Carbonic anhydrase 9)

Quality Control

Batch: A257801 Purity: 99% Protein concentration: 7.98mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Carbonic Anhydrase Carbonic Anhydrase I Carbonic Anhydrase IX Carbonic Anhydrase XII Others
U-104 (SLC-0111) 11
Tioxolone 0
Indisulam (E7070) 3 CDK2,cyclin E
Benzenesulfonamide 1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to Carbonic Anhydrase IX (CAIX) / Carbonic Anhydrase 9 (CA9), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD.

Product Details

CAS No. 916138-87-9
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.